0 Citations
0 Reads
A randomized, double-blind, multicenter, phase II, three-arm, placebo-control study of apatinib as third-line treatment in patients with metastatic gastric carcinoma.
Li, J
Qin, S
Xu, J
Guo, W J
Xiong, J P
Bai, Y
Sun, G
Yang, Y
Wang, L
Xu, N
Cheng, Y
Zhe Hai, W
Zheng, L
Tao, M
2011-5-20
Summary
--
Keywords
--
Select Groups
Select Contacts
swap_vert Order by date
Order by date Order by name